Cidara to Present at ESMO Targeted Anticancer Therapies Congress
Cidara Therapeutics (NASDAQ: CDTX) announced it will present pharmacokinetic study highlights of its CD73-targeting drug-Fc conjugate (DFC) oncology candidate at the ESMO TAT Congress in Paris from March 6-8, 2023. The studies showcase the drug's ability to inhibit CD73, a component of the adenosine pathway involved in immune evasion in solid tumors. The lead candidate, CBO-212, addresses the limitations of traditional small molecule and monoclonal antibody therapies. The abstract presentation is scheduled for March 6, 2023, at 5:35 p.m. CET in Hall Bordeaux, Palais des Congrès de Paris.
- None.
- None.
SAN DIEGO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to help improve the standard of care for patients facing serious diseases, today announced that it will present highlights from pharmacokinetic studies of a CD73-targeting drug-Fc conjugate (DFC) oncology candidate from the Company’s Cloudbreak® platform at the ESMO Targeted Anticancer Therapies Congress (ESMO TAT) in Paris, March 6-8, 2023. The studies evaluated the inhibition of CD73 in cell-free and cell-based assays.
Cidara’s lead oncology candidate targets CD73 in the adenosine pathway, which contributes to immune evasion in solid cancers by flooding the tumor microenvironment with adenosine, a potent immune cell suppressor. CD73 is highly expressed on a variety of tumor and stromal cells as well as immunosuppressive cell populations, such as regulatory T cells and myeloid-derived suppressor cells. CD421 is designed to address the potency, efficacy, pharmacokinetic and safety limitations of small molecule and monoclonal antibody candidates targeting CD73.
Abstract presentation details are as follows:
Title: Discovery of CBO-212, a first-in-class Drug Fc-Conjugate (DFC), targeting CD73 in Cancer
Presenters: James Levin, Ph.D., Simon Doehrmann, Ph.D.
Presentation Number: 45P
Session Date/Time: Monday, March 6, 2023, 5:35 p.m. CET
Session Location: Hall Bordeaux, Palais des Congrès de Paris
To view the full schedule, visit the ESMO TAT website here. A copy of the abstract can be accessed in the Publications section of the Cidara website once the presentation concludes.
About Cloudbreak® DFCs
Cidara is developing a new generation of immunotherapeutic agents from its Cloudbreak platform that couple potent drugs to a human antibody fragment (Fc). These highly potent, long-acting drug-Fc conjugates (DFCs) are designed to inhibit specific disease targets while simultaneously engaging the immune system. In addition to multiple oncology programs, Cidara is advancing its antiviral DFC CD388 through Phase 1 and Phase 2a clinical trials in partnership with Janssen for the universal prevention and treatment of influenza. Cidara is also advancing DFC programs to target other life-threatening viruses, such as SARS-CoV-2.
About Cidara Therapeutics
Cidara is developing long-acting therapeutics designed to improve the standard of care for patients facing serious diseases. The Company’s portfolio is comprised of new approaches aimed at transforming existing treatment and prevention paradigms, first with its lead Phase 3 antifungal candidate, rezafungin, in addition to drug-Fc conjugates (DFCs) targeting viral and oncology diseases from Cidara’s proprietary Cloudbreak® platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “anticipates,” “expect,” “may,” “plan” or “will”. Forward-looking statements in this release include, but are not limited to, statements related to whether nonclinical data generated for a CD73 targeting DFC will be predictive of safety or efficacy in humans. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, such as unanticipated delays in or negative results from Cidara’s preclinical or clinical trials, delays in action by regulatory authorities due to limitations on inspections and other COVID-19-related effects, and impacts of the COVID-19 pandemic or other obstacles on the enrollment of patients or other aspects of CD388 development. These and other risks are identified under the caption “Risk Factors” in Cidara’s most recent Quarterly Report on Form 10-Q and other filings subsequently made with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Cidara does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
Patrick Bursey
LifeSci Communications
(203) 430-9545
pbursey@lifescicomms.com
FAQ
What is the presentation date for Cidara's CD73-targeting drug-Fc conjugate at ESMO TAT?
Where is the ESMO Targeted Anticancer Therapies Congress being held?
What is the focus of Cidara's lead oncology candidate?
What innovative platform is used for Cidara's drug candidates?
What are drug-Fc conjugates aimed at achieving?
